Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system

Hypertension

Volumn 59, Issue 5, 2012, Pages 966-972

  Latouche, Celine ^a   El Moghrabi, Soumaya ^a   Messaoudi, Smail ^a   Cat, Aurélie Nguyen Dinh ^a   Hernandez Diaz, Ivan ^b   De La Rosa, Diego Alvarez ^b   Perret, Claudine ^a   Andrés, Natalia López ^a   Rossignol, Patrick ^a,c   Zannad, Faiez ^a,c   Farman, Nicolette ^a   Jaisser, Frederic ^a  

^a INSERM   (France)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Cardiac cell lines; Cardiomyocyte; Chromatin immunoprecipitation; Mineralocorticoid receptor; Transgenic mice

Indexed keywords

ALDOSTERONE; BETA ACTIN; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; HEART MUSCLE CELL; IN VITRO STUDY; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UPREGULATION; WILD TYPE;

ACUTE-PHASE PROTEINS; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CARDIOVASCULAR SYSTEM; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HUMANS; LIPOCALINS; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; ONCOGENE PROTEINS; RANDOM ALLOCATION; RECEPTORS, MINERALOCORTICOID; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84860222801     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.187872     Document Type: Article

References (43)

1. Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol. 2001;280:F181-F192.
2. Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol. 2012;350: 266-272.
3. Zennaro MC, Caprio M, Feve B. Mineralocorticoid receptors in the metabolic syndrome. Trends Endocrinol Metab. 2009;20:444-451.
4. Sainte Marie Y, Toulon A, Paus R, Maubec E, Cherfa A, Grossin M, Descamps V, Clemessy M, Gasc JM, Peuchmaur M, Glick A, Farman N, Jaisser F. Targeted skin overexpression of the mineralocorticoid receptor in mice causes epidermal atrophy, premature skin barrier formation, eye abnormalities, and alopecia. Am J Pathol. 2007;171:846-860. (Pubitemid 47440984)
5. Zhao M, Valamanesh F, Celerier I, Savoldelli M, Jonet L, Jeanny JC, Jaisser F, Farman N, Behar-Cohen F. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in muller glial cells. FASEB J. 2010;24:3405-3415.
6. Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouve P, Wassef M, Swynghedauw B, Delcayre C. Biological determinants of aldosteroneinduced cardiac fibrosis in rats. Hypertension. 1995;26:971-978.
7. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz. 2000;25:299-306. (Pubitemid 30422181)
8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study investigators. N Engl J Med. 1999;341:709-717. (Pubitemid 29407370)
9. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. (Pubitemid 36384098)
10. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
11. Flower DR, North AC, Sansom CE. The lipocalin protein family: structural and sequence overview. Biochim Biophys Acta. 2000; 1482:9-24.
12. Grzyb J, Latowski D, Strzalka K. Lipocalins: a family portrait. J Plant Physiol. 2006;163:895-915.
13. Devarajan P. Emerging biomarkers of acute kidney injury. Contrib Nephrol. 2007;156:203-212.
14. Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, Chow WS, Wat NM, Xu JY, Hoo RL, Xu A. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem. 2007;53:34-41. (Pubitemid 46047761)
15. Catalan V, Gomez-Ambrosi J, Rodriguez A, Ramirez B, Silva C, Rotellar F, Gil MJ, Cienfuegos JA, Salvador J, Fruhbeck G. Increased adipose tissue expression of lipocalin-2 in obesity is related to inflammation and matrix metalloproteinase-2 and metalloproteinase-9 activities in humans. J Mol Med. 2009;87:803-813.
16. Bolignano D, Basile G, Parisi P, Coppolino G, Nicocia G, Buemi M. Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Res. 2009;12:7-14.
17. Yndestad A, Landro L, Ueland T, Dahl CP, Flo TH, Vinge LE, Espevik T, Froland SS, Husberg C, Christensen G, Dickstein K, Kjekshus J, Oie E, Gullestad L, Aukrust P. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J. 2009;30:1229-1236.
18. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, Cat AN, Royer A, Le Quang K, Charpentier F, Demolombe S, Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME, Delcayre C, Fishman GI, Farman N, Escoubet B, Jaisser F. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:3025-3033. (Pubitemid 40847778)
19. Sainte-Marie Y, Nguyen Dinh Cat A, Perrier R, Mangin L, Soukaseum C, Peuchmaur M, Tronche F, Farman N, Escoubet B, Benitah JP, Jaisser F. Conditional glucocorticoid receptor expression in the heart induces atrioventricular block. Faseb J. 2007;21:3133-3141. (Pubitemid 47565533)
20. Latouche C, Sainte-Marie Y, Steenman M, Castro Chaves P, Naray-Fejes-Toth A, Fejes-Toth G, Farman N, Jaisser F. Molecular signature of mineralocorticoid receptor signaling in cardiomyocytes: from cultured cells to mouse heart. Endocrinology. 2010;151:4467-4476.
21. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, Izzo NJ Jr. Hl-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA. 1998;95:2979-2984. (Pubitemid 28135840)
22. Hernandez-Diaz I, Giraldez T, Arnau MR, Smits VA, Jaisser F, Farman N, Alvarez de la Rosa D. The mineralocorticoid receptor is a constitutive nuclear factor in cardiomyocytes due to hyperactive nuclear localization signals. Endocrinology. 2010;151:3888-3899.
23. Kobayashi M, Inoue K, Warabi E, Minami T, Kodama T. A simple method of isolating mouse aortic endothelial cells. J Atheroscler Thromb. 2005;12:138-142.
24. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, Schiffrin EL. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension. 2005;45:773-779. (Pubitemid 40418380)
25. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006;47:656-664. (Pubitemid 43740235)
26. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, Takeda Y, Yoshida J, Miwa T, Okamoto M, Masuyama T, Nonaka Y, Hori M. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol. 2007;292: R946-R954. (Pubitemid 46207752)
27. Ding L, Hanawa H, Ota Y, Hasegawa G, Hao K, Asami F, Watanabe R, Yoshida T, Toba K, Yoshida K, Ogura M, Kodama M, Aizawa Y. Lipocalin-2/neutrophil gelatinase-B associated lipocalin is strongly induced in hearts of rats with autoimmune myocarditis and in human myocarditis. Circ J. 2010;74:523-530.
28. Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, Thoren P, Hansson GK. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol. 2006;26:136-142. (Pubitemid 43732240)
29. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL): modulation of MMP-9 activity by NGAL. J Biol Chem. 2001;276: 37258-37265.
30. Bu DX, Hemdahl AL, Gabrielsen A, Fuxe J, Zhu C, Eriksson P, Yan ZQ. Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-B. Am J Pathol. 2006;169:2245-2253. (Pubitemid 351181982)
31. Karlsen JR, Borregaard N, Cowland JB. Induction of neutrophil gelatinase-associated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-is controlled by IαB-zeta but neither by c/EBP-nor c/EBP-. J Biol Chem. 2010;285:14088-14100.
32. De Bosscher K, Vanden Berghe W, Haegeman G. Cross-talk between nuclear receptors and nuclear factor b. Oncogene. 2006;25:6868-6886.
33. Kolla V, Litwack G. Inhibition of mineralocorticoid-mediated transcription by NF-B. Arch Biochem Biophys. 2000;383:38-45.
34. Bergmann A, Eulenberg C, Wellner M, Rolle S, Luft F, Kettritz R. Aldosterone abrogates nuclear factor B-mediated tumor necrosis factor production in human neutrophils via the mineralocorticoid receptor. Hypertension. 2010;55:370-379.
35. Leroy V, De Seigneux S, Agassiz V, Hasler U, Rafestin-Oblin ME, Vinciguerra M, Martin PY, Feraille E. Aldosterone activates NF-B in the collecting duct. J Am Soc Nephrol. 2009;20:131-144.
36. Devarajan P. Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle. Cancer Ther. 2007;5:463-470.
37. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell. 2002;10: 1033-1043. (Pubitemid 36001971)
38. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2007;18:407-413. (Pubitemid 46193306)
39. Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF, Wu Y, Arlinghaus RB. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res. 2009;69:8579-8584.
40. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM, Chen X, Li JY, Weiss S, Mishra J, Cheema FH, Markowitz G, Suganami T, Sawai K, Mukoyama M, Kunis C, D'Agati V, Devarajan P, Barasch J. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest. 2005; 115:610-621. (Pubitemid 40322235)
41. Viau A, El Karoui K, Laouari D, Burtin M, Nguyen C, Mori K, Pillebout E, Berger T, Mak TW, Knebelmann B, Friedlander G, Barasch J, Terzi F. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest. 2010;120:4065-4076.
42. Bolignano D, Coppolino G, Lacquaniti A, Buemi M. From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. Eur J Clin Investig. 2010;40:273-276.
43. Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS, Choi DS, Oh DJ, Park CG. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol. 2008;158:203-207. (Pubitemid 351298537)